Drug safety surveillance using de-identified EMR and claims data: issues and challenges
about
The coming age of data-driven medicine: translational bioinformatics' next frontierHarmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR projectGeneralized enrichment analysis improves the detection of adverse drug events from the biomedical literaturePharmacovigilance Using Clinical NotesUse of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data.Translational bioinformatics embraces big data.Text mining for adverse drug events: the promise, challenges, and state of the art.Cross-terminology mapping challenges: a demonstration using medication terminological systems.Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes.Using temporal patterns in medical records to discern adverse drug events from indications.Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review.Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records.Complex temporal topic evolution modelling using the Kullback-Leibler divergence and the Bhattacharyya distanceADEpedia 2.0: Integration of Normalized Adverse Drug Events (ADEs) Knowledge from the UMLS.Development of a detection algorithm for statin-induced myopathy using electronic medical records.Deep learning for pharmacovigilance: recurrent neural network architectures for labeling adverse drug reactions in Twitter posts.Computational Drug Repositioning Using Continuous Self-Controlled Case SeriesDetection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm.
P2860
Q28386235-BA8B38C9-1A55-409E-902F-5A50ADB02628Q28709512-F05B6B74-805B-4D35-B34D-9D10F0B323CCQ28829259-8EB88BEC-D1C9-4CD8-AE84-ECA1FC38F4F9Q30058397-47C597DE-E695-431A-B0E6-953CCC048AB9Q34089235-D89F6A0C-83B7-42A6-A98C-FEC27A134C02Q34378848-8A5F9AA9-A086-4DB5-ADA9-E54595869245Q34442663-FB54EB78-242F-4582-AC13-E902F0F8F2DEQ35430852-D155E45C-20BA-47F0-A33B-5F764D894F32Q35914408-080C215C-AAF4-4CF4-97AF-AAF92A9B962CQ36082966-E64EE2B5-7891-49C2-94DD-FDF2D66BAD68Q36413039-4777C535-254C-4882-BEB6-88CE7C77CDF3Q36460556-68DF2289-B474-424B-962F-3EF1E4453029Q37298012-97422B94-4BFE-4EBB-939B-1B3B81776047Q37354400-0CF1AB87-3DD4-43E6-8EC0-6E234F66C92AQ38093266-5DE804CD-8D3E-4BDA-BF57-0DC6892ECE93Q38379019-E9BEB56B-E766-4E61-B270-6477FDAE8D7EQ38895303-29D8DB2C-C77F-4D1E-B005-70B040BA2515Q51452812-E3DD1245-5408-46F7-81FC-D2BBD2A10482
P2860
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@ast
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@en
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@nl
type
label
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@ast
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@en
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@nl
prefLabel
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@ast
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@en
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@nl
P2860
P3181
P1476
Drug safety surveillance using de-identified EMR and claims data: issues and challenges
@en
P2093
Prakash M Nadkarni
P2860
P3181
P356
10.1136/JAMIA.2010.008607
P407
P577
2010-01-01T00:00:00Z